Biotech

New Culture Raises $3.5 Million To Disrupt The Dairy Industry | 9/17/2019

… and the traditional cheesemaking process, New Culture is making dairy cheese that is sustainable, healthy, ethical, and indistinguishable from animal-based dairy cheese in taste, texture, and function. New Culture participated in the IndieBio biotech accelerator program, which has helped grow the businesses of food startups like Memphis Meats, Clara Foods, and New Age Meats. ADVERTISEMENT “It’s fantastic to have the support of our investors as we look to grow …

Couple stole trade secrets from U.S. children’s hospital to market their Chinese biotech, prosecutors say | 9/17/2019

… 46, worked for Nationwide Children’s Hospital in Dayton, Ohio, until just under two years ago, prosecutors said Monday. The couple worked at the hospital in separate research labs for a decade, and founded a biotech company in China in 2015 that relied on many of the same technological and scientific advances. The research largely focused on exosomes — small, bubble-like groups of molecules released by cells and increasingly used by …

Follow Biotech:    

Alder BioPharma to be Acquired by Lundbeck in US$2B Deal | 9/17/2019

… to acquire all of the outstanding shares of Alder BioPharma at US$18 each up front with an additional US$2 per share once eptinezumab is approved by the European Medicines Agency. Is the biotech market the perfect mesh between the technology and pharmaceutical market? Read our FREE outlook report below! Shares of Alder BioPharma skyrocketed nearly 84 percent from its previous close of US$10.06 to finish Monday’s trading …

Cannara Biotech (CNSX:LOVE) Trading 8.8% Higher - Transcript Daily | 9/17/2019

Shares of Cannara Biotech (CNSX:LOVE) traded up 8.8% during trading on Monday . The stock traded as high as $0.19 and last traded at $0.19, 1,023,762 shares changed hands during mid-day trading. The stock had previously closed at $0.17. The firm has a fifty day simple moving average of $0.15. Cannara Biotech Company Profile ( CNSX:LOVE ) Cannara Biotech Inc is a vertically integrated cannabis company building the largest indoor …

The first ‘right-to-try’ CRO launches | 9/17/2019

The first ‘right-to-try’ CRO launches Biotech Mag As the White House continues its push for the benefits of “right to try,” the first CRO associated with the law has come onto the stage. Other Posts from Biotech Mag …

ERT Expands its Commitment to Heart Health and Research | PRWeb | 9/16/2019

… teams in Philadelphia. In 2014, Phyllis Sudman was named the 2014 Woman of Worth National Honoree by L’Oréal Paris, beating out more than 4,300 other women. Darren Sudman received the 2017 Be Well Philly Health Hero Award from Philadelphia Magazine and Independence Blue Cross. For more information please visit http://www.simonsheart.org. Share article on social media or email: View article via …

Interpace Enters Strategic Partnership Agreement with Genecast Biotechnology to Partner with Biopharma Solutions in China | 9/16/2019

… s subsidiary, Interpace BioPharma Inc. (“Interpace”, “Interpace BioPharma” or the “Company”) today announced that it has entered into a partnership agreement to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (“PRC”). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a …

Kineticos Prepares for Next Phase of Growth Expand | 9/16/2019

… and pharmaceutical industries building out commercial capabilities, leading marketing and sales efforts, and cultivating strong thought leader relationships. His prior experience and positions include Executive Commercial, Sales and Marketing Leadership, and Scientific roles at Novo Nordisk Pharmaceuticals, Sigma-Aldrich Corp, Charles Rivers Labs , and the United States EPA. Shailesh Maingi , CEO and Founder of Kineticos, stated, «We’re thrilled to have Philip as he brings a rich commercial background to the …

Global Colorectal Cancer Market Review & Outlook (2017-2026) - ResearchAndMarkets.com | Business & Finance | manchestertimes.com | Business Wire | 9/16/2019

The “Colorectal Cancer - Global Market Outlook (2017-2026)” report has been added to ResearchAndMarkets.com ‘s offering. The Global Colorectal Cancer market accounted for $9.22 billion in 2017 and is expected to reach $13.01 billion by 2026 growing at a CAGR of 3.9% during the forecast period. Introduction of new and improved therapies and drugs, the rising uptake of higher-priced branded therapies, and several initiatives by governments and private organizations are …

Fierce 15: Where are they now? | FierceBiotech | 9/16/2019

… anyway, thanks to the big names involved in the company. George Scangos (Vir) George Scangos, the former Biogen frontman, signed on to head the new California company as the Bill & Melinda Gates Foundation and ARCH Venture Partners delivered $150 million in startup capital. Not a bad place to start. Then in 2017, it emerged from the shadows and outlined the details of a pipeline focused on infectious disease. And true …

Amplyx boosts pipeline with Novartis antiviral, unveils phase 2 data for lead antifungal | FierceBiotech | 9/16/2019

… the human body, so there’s no target-driven toxicity in patients.” RELATED: Spying a chance to stop a ‘catastrophic threat,’ VCs funnel $67M into Amplyx to trial a broad-spectrum antifungal As for the Novartis deal, Amplyx picked up the exclusive worldwide rights to a monoclonal antibody, MAU868, but kept financial details under wraps. The drug targets BK virus, a virus that most people catch in childhood and that can …

Foghorn and Rgenix nab Agios, Roche veterans as new CMOs | FierceBiotech | 9/16/2019

Smaller biotechs are continuing their biopharma hiring spree as two startups nab some big names for their aspiring cancer drug research. First up is New York biotech Rgenix, which a year ago raised a $40 million in series C to carry out early and midstage trials for a pair of oncology meds: an immunotherapy for solid tumors and a cancer metabolism inhibitor for gastrointestinal cancers. The biotech has hired Robert …

Fate Therapeutics: Pioneer In iPSC Space Continues To Make Progress - Fate Therapeutics, Inc. (NASDAQ:FATE) | Seeking Alpha | 9/16/2019

… a clinical manufacturing campaign was estimated to cost less than $1 million per campaign and yield about 300 doses (essentially producing product for less than $5000 per dose). As for institutional investors of note , RedMile Group continues to own over 10 million shares. Insider selling over the past couple of quarters does not inspire confidence. Keep in mind that the iPSC field is moving forward rapidly as other players get …

Gens & Associates Announce Premier Benchmark Membership Program | PRWeb | 9/16/2019

Gens & Associates today announced the launch of their Benchmark Premier Membership. The program gives members access to the latest and most respected Regulatory Information Management (RIM) benchmarking data and access to global expertise. The program is designed to expand the company’s research platform while providing customized actionable guidance to help organizations tackle the complexities of regulatory cost pressures, evolving e-submissions standards, global workflows and automated connections to other functional …

Exclusive: The FBI Hunts Chinese Spies At An Elite American Children’s Hospital | Forbes | 9/16/2019

… Zhou’s iPhones were seized upon his arrest at San Diego International Airport, when he was returning to the U.S. from China, a search warrant application obtained by Forbes revealed. Beyond Ohio and Florida, at MD Anderson Cancer Center in Houston, anxiety within the Chinese community has peaked in recent months following an FBI raid on the medical facility and an investigation into two employees there, again a husband and wife …

Do Options Traders Know Something About Puma Biotech (PBYI) Stock We Don’t? | Zacks | 9/16/2019

… off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy. What do the Analysts Think? Clearly, options traders are pricing in a big move for Puma Biotech shares, but what is the fundamental picture for the company? Currently, Puma Biotech is a Zacks Rank 3 (Hold) in the Medical – Biomedical and Genetics industry that ranks in the Top 31% of our Zacks …

5 Stocks in the Limelight After Recent Broker Rating Upgrade | Zacks | 9/16/2019

… IL. The company’s current-quarter earnings are projected to grow 5.6% while that of its industry are expected to decline 12.9%. You can see the complete list of today’s Zacks 1 Rank stocks here . CVS Health ( CVS - Free Report ) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. The company, carrying a Zacks Rank 2 (Buy), is headquartered in Woonsocket, RI. The company has …

Biotechnology Market is Estimated to be Valued $727.1 Billion By 2025: Grand View Research, Inc | 9/16/2019

… diagnosis, prognosis and biopharmaceutical development is estimated to propel the market Decreasing costs and rise in number of services in this segment are expected to drive segment with lucrative avenues North American pharmaceutical and biotech companies have experienced great success in the recent years resulting in larger share Introduction of technologically advanced products and presence of various biotechnology based programs such as the UC Davis Biotechnology Program, the University of …

PPF Expands its Investment in the Healthcare Sector Through Acquisition of Significant Stake in T Cell Therapy Company Autolus Therapeutics | Business & Finance | manchestertimes.com | Business Wire | 9/16/2019

… biotechnology sector. “Our investment in Autolus confirms the long term commitment of PPF and SOTIO to build a strong biotechnology portfolio developing a broad range of its own oncology products and investing in various biotech companies with promising new therapies.” View source version on businesswire.com : https://www.businesswire.com/news/home/20190916005504/en/ CONTACT: Jitka Tkadlecová T +420 224 174 410 M +420 725 461 574 E-mail:[email protected] Head of …

Kas Subramanian, PhD Joins Applied BioMath, LLC as Senior Director of Preclinical Modeling | PR Newswire | 9/16/2019

… modeling, simulation, and analysis to de-risk drug research and development, is proud to welcome Kas Subramanian, PhD as Senior Director of Preclinical Modeling. In this role, Kas will work closely with pharmaceutical and biotech teams to build fit-for-purpose mathematical models that help drive decisions in drug development. Prior to joining Applied BioMath, Kas led the Bioinformatics group at Syngene International which integrated data and created models to …

Food and Drug Administration

Positive results bring early halt to trial of dementia psychosis drug Nuplazid | 9/10/2019

Biotech Positive results bring early halt to trial of dementia psychosis drug Nuplazid With a market value of $6.5 billion, Acadia is one of the largest biomedical companies in San Diego County. (Acadia Pharmaceuticals) After … The company said Monday it will talk with the U.S. Food and Drug Administration next year about approving the drug, Nuplazid. No drug is currently approved for dementia-related psychosis. At the close of trading

Allergan and Molecular Partners Announce Acceptance of U.S. FDA Biologics License Application and Validation of EMA Marketing Authorisation for Abicipar pegol in Patients with Neovascular (Wet) Age-related Macular Degeneration | PR Newswire | 9/9/2019

DUBLIN Allergan plc (NYSE: AGN ), a leading global pharmaceutical company with a heritage of more than 70 years in eye care, and Molecular Partners (SIX: MOLN), a clinical-stage biotechnology company developing a new class of drugs known as DARPin® platform, today announced that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and the European Medicines Agency (EMA) has validated a Marketing Authorisation Application …

Clinical Data

Innate Pharma reports first half 2019 financial results and business update – Company Announcement - FT.com | Financial Times | 9/13/2019

… AND BUSINESS UPDATE Initiation of multi-cohort IPH4102 Phase II clinical trial (TELLOMAK) Sézary Syndrome cohort designed to be pivotal; preclinical data supports evaluating larger subsets of patients with T-cell lymphoma Preliminary data expected … anti-CD39, paid to Novo Nordisk A/S and Orega Biotech, for $15m (or €13.1m) and €7.0m, respectively. As of June 30, 2019, financial liabilities amounted to €5.0m compared to €4.5m as of December 31 …

Children’s Tumor Foundation Hosts NF Innovation Week in San Francisco | PRWeb | 9/13/2019

… NF field - will gather at the Google Launchpad for three intensive days (Sep 13-15) to ‘hack’ genomic, research, and imaging/clinical data from the NF Data Portal, and bring their unique insights and experiences to … source data, and an NF platform that attracts pharma and biotech to the NF space, and helps ‘de-risks’ research about a somewhat still relatively not-well-known disease. This is done through the Foundation’s …

AMA

Former Novartis CEO and Eli Lilly’s Drug Development Leader are Featured Keynote Speakers at Veeva R&D Summit | Business Wire | 8/22/2019

… one of the largest pipelines of self-originated drugs in the industry. Paul Sehkri, CEO of eGenesis, a leading-edge biotech focused on xenotransplantation, will discuss with Mr. Jimenez the impact of innovations such as … Pharma. 2019 Veeva R&D Summit platinum sponsors include Accenture, Amazon Web Services, Kinapse, NNIT, PWC, and Valiance. Gold sponsors include C3i Solutions, CGI, Daelight Solutions, Deloitte, Eagle Productivity, FME, GenPact, Ideagen PLC, LMK Clinical …

Pfizer adds $500M to gene therapy manufacturing plant where it will hire 300 workers | FiercePharma | 8/21/2019

… development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now. Start Now “We’re excited to build this new … in Sanford that it acquired when it bought gene therapies biotech Bamboo Therapeutics. At that time, it projected the expansion would come with about 40 jobs. The 300 hires it now intends to make will …

Regenerative Medicine

When Will Avita Medical Limited (ASX:AVH) Turn A Profit? | Yahoo News | 9/12/2019

… ASX:AVH) Turn A Profit? Simply Wall St Reblog Avita Medical Limited’s ( ASX:AVH ) : Avita Medical Limited operates as a regenerative medicine company in the Asia Pacific, Europe, the Middle East, Africa, and the Americas … our latest analysis for Avita Medical Consensus from the 2 Biotechs analysts is AVH is on the verge of breakeven. They anticipate the company to incur a final loss in 2021, before generating positive profits …

AIVITA Biomedical Launches Professional ROOT of SKIN™ MD Skincare Line in Japan | PR Newswire | 9/10/2019

IRVINE, Calif. , Sept. 10, AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced today the launch of the Company’s professional ROOT of SKIN™ MD brand of rejuvenating skincare products in Japan … advancement of commercial and clinical-stage programs utilizing curative and regenerative medicines. Founded in 2016 by pioneers in the stem cell industry, AIVITA Biomedical utilizes its expertise in stem cell growth and directed, high-purity

Big Pharma

Gain Therapeutics SA Announces Jeffrey Riley to join its Board of Directors | Business Wire | 9/12/2019

LUGANO, Switzerland–(BUSINESS WIRE)–Sep 12, 2019– Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in CNS diseases, today announced that … 1.5B in equity and debt instruments. He has worked for big pharma (SmithKline Beecham and Pfizer), venture capital (Queensland Biocapital Fund / QIC) and numerous biotechnology companies in his capacity of business development and general management

Changing of the guard at Swiss biotech Vifor; nabs Sanofi exec as new CMO | FierceBiotech | 9/11/2019

Big Pharma where he was its global therapeutic area head, responsible for diabetes, cardiovascular and metabolism development for three years. Before this, he worked for more than 11 years at diabetes specialist Novo Nordisk as its VP, and later its head of clinical, medical and regulatory. At Vifor, he will now lead its clinical development, drug safety and medical affairs. FREE DAILY NEWSLETTER Like this story? Subscribe to FierceBiotech! Biopharma …

ACA

CRISPR slows the growth of triple-negative breast cancer in mice | FierceBiotech | 8/26/2019

… Academy of Sciences. FREE DAILY NEWSLETTER Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go. SUBSCRIBE …

Friday, August 23, 2019 | Kaiser Health News | 8/23/2019

… shift on their party’s top 2020 issue. “Medicare for All” remains hugely popular, but majorities say they’d prefer building on “Obamacare” to expand coverage instead of a new government program that replaces America’s mix of … 24. (Burton, 8/22) Bloomberg: The FDA Is Flexing Its Muscles Biotechnology companies often have both devoted fans and detractors. But there’s one constituency they’d be wise not to anger: U.S. regulators. In the past few …

National Institutes of Health

AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer’s and Other CNS Conditions | PR Newswire | 9/11/2019

… property was based on over 15 years of basic research supported by the National Institute on Aging, part of the National Institutes of Health. “Pre-clinical GABA-A a5 and Phase-3 AGB101 show promise … venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded over $115 million to fund more than 590 Alzheimer’s drug discovery programs and …

Next Up In China Trade War: Biotech Purge? | Forbes | 9/4/2019

… the U.S. has increasingly lost trust in China as a good faith partner. Next up in the China trade war: biotech and Chinese cancer researchers are being put on notice. Are biotech companies really that … in both places simultaneously, while also being the beneficiaries of National Institutes of Health grants. I am not sure if any of these scientists have ever been accused or convicted of spying, though,” says Cole …

American Society of Clinical Oncology

Zai Lab Announces Financial Results and Corporate Update for the Six Months Ended June 30, 2019 | Globe Newswire | 9/3/2019

… other oncology candidates. With a growing pipeline and execution progress, Zai Lab has established a global reputation as a China biotech pioneer. Zai Lab is already an integrated biopharma with nearly 600 employees across six … metastatic breast cancer and presented the primary analysis at the American Society of Clinical Oncology (ASCO) in June 2019. The trial met the first sequential primary endpoint of prolongation of PFS in patients treated with …

Yes, Amgen overpaid for Otezla—but that doesn’t make it a mistake: analysts | FiercePharma | 8/28/2019

… the numbers on Amgen’s planned $13.4 billion purchase of Celgene’s psoriasis blockbuster Otezla, and now they’ve reached a consensus: The biotech giant overpaid for the drug. Then again, if anyone can make the purchase pay … types, is already generating excitement on the Street. At the American Society of Clinical Oncology annual meeting in June, the company said that in a small phase 1 study AMG510 halted tumor growth in non …

ACO

World Therapeutic Drug Monitoring (TDM) Market Outlook to 2028 with Market Values in Major Regions | PR Newswire | 8/27/2019

… PharmaBiotech has been added to ResearchAndMarkets.com’s offering. This report deals with therapeutic drug monitoring, a multi-disciplinary clinical specialty, aimed at improving patient care by monitoring drug levels in the blood to individually adjust the dose of drugs for improving outcome. TDM is viewed as a component of personalized medicine that interacts with several other disciplines including pharmacokinetics and pharmacogenetics. One chapter is devoted to monitoring of drugs of abuse …

Star biotech analyst Mark Schoenebaum, loved for his humor as much as his work, dies | FierceBiotech | 8/26/2019

… FierceBiotech and FiercePharma. But Schoenebaum wasn’t all work and no play. “He was a model of hard work and talent, leavened with warmth, grace, humility & a delightfully sly sense of humor- @roncohenshair owes him a special debt. Condolences to his family and all of us who admired & loved him,” wrote Acorda CEO Ron Cohen in a tweet Monday morning. Cohen’s Twitter handle is a product of the “Best Hair in …

NIH

AgeneBio Announces Additional Funding to Advance Novel GABA-A Therapeutic Program to Address Alzheimer’s and Other CNS Conditions | PR Newswire | 9/11/2019

BALTIMORE , Sept. 11, Building on previous progress in the NIH Blueprint Neurotherapeutics program, AgeneBio today announced it has received significant additional resources to accelerate the development of their GABA-A a5 Positive Allosteric Modulation (PAM … venture philanthropy model to support research in academia and the biotech industry. Through the generosity of its donors, the ADDF has awarded over $115 million to fund more than 590 Alzheimer’s drug discovery programs and

Singerman Real Estate (SRE) and HATCHspaces® JV acquire 160,980 SF Thousand Oaks Life Science Campus – HATCHcampus @Conejo Spectrum | Business Wire | 9/5/2019

… biotech forest. Amgen’s headquarter presence is having that same impact in the region.” “The Los Angeles region is experiencing its moment in the life sciences,” says HATCHspaces® Co-Founder Howard Kozloff. “Over $1 billion of annual investment from the NIH alone flows into the hands of extraordinary researchers and supporting institutions in the Los Angeles region.” HATCHspaces® is now on their fifth science-focused acquisition in the greater Los Angeles …

Merck

Pharmacy Times Continuing Education™ to Host Directions in Oncology Pharmacy™ Conference in Chicago | Business Wire | 9/12/2019

Merck Sharp & Dohme Corp.; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc. For more information and to register for the conference, click here. About Pharmacy Times Continuing Education™ Pharmacy Times Continuing Education ™ ( PT CE) is a leader in continuing education for retail, health-system, managed care and specialty pharmacists. PT CE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE …

Isofol Announces that an Abstract has been Accepted for Presentation at the 2019 ESMO Congress | PR Newswire | 9/12/2019

… largest oncology conference in Europe and will be attended by approximately 25,000 clinicians, researchers and representatives of the pharmaceutical and biotechnology sector. The poster will be published on-line via the ESMO website on September … free survival. Isofol holds a worldwide exclusive license agreement with Merck KGaA, Darmstadt, Germany to develop and commercialize arfolitixorin for oncology indications. Isofol Medical AB (publ) is traded on the Nasdaq First North Premier. Certified …

Pfizer

Chutes & Ladders—Bayer trims 2 execs in corporate reshuffling | FierceBiotech | 9/13/2019

… FierceBiotech! Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go. Pfizer spinout Cerevel hires Coles as CEO Cerevel Tony Coles will take …

Gain Therapeutics SA Announces Jeffrey Riley to join its Board of Directors | Business Wire | 9/12/2019

LUGANO, Switzerland–(BUSINESS WIRE)–Sep 12, 2019– Gain Therapeutics SA, a biotechnology company discovering and developing novel therapeutics to target lysosomal enzymes involved in inborn errors of metabolism and in CNS diseases, today announced that … instruments. He has worked for big pharma (SmithKline Beecham and Pfizer), venture capital (Queensland Biocapital Fund / QIC) and numerous biotechnology companies in his capacity of business development and general management. “We are delighted to have

Novartis

Dr. John Ryals added to Biosortia Pharmaceutical Board of Directors | PR Newswire | 9/11/2019

… said Ross Youngs , Biosortia’s Founder, Chairman and CEO. “John has a proven track record of building professional and scientifically successful biotech companies. John is also a trailblazer who has advanced the understanding of human health … experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He is now the Chairman Emeritus, Founder and Board Member at Metabolon. Prior to founding Metabolon, Dr. Ryals was chief executive …

Next Up In China Trade War: Biotech Purge? | Forbes | 9/4/2019

… the U.S. has increasingly lost trust in China as a good faith partner. Next up in the China trade war: biotech and Chinese cancer researchers are being put on notice. Are biotech companies really that … national security concerns regarding biotech, Stratfor research analysts believe. A Novartis research lab in Shanghai; their third largest after Europe and the U.S. Biotech is part of the Made in China 2025 policy, which has …

Celgene

Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says - Barron’s | 9/13/2019

Bristol-Meyers Squibb Co. medication Photograph by Daniel Acker/Bloomberg Things are looking up for Bristol-Myers Squibb , according to one analyst at JPMorgan , even with the stock down 18.3% over the past 12 months. “Overall, we see far more paths to upside…than downside…for the stock from here,” wrote the bank’s Christ Schott in a note published Thursday. Scott highlighted the high price that the biotech firm Celgene

Pharmacy Times Continuing Education™ to Host Directions in Oncology Pharmacy™ Conference in Chicago | Business Wire | 9/12/2019

Celgene Corporation; Eisai; Jazz Pharmaceuticals; Merck Sharp & Dohme Corp.; and Pharmacyclics LLC, an AbbVie Company and Janssen Biotech Inc. For more information and to register for the conference, click here. About Pharmacy Times Continuing Education™ Pharmacy Times Continuing Education ™ ( PT CE) is a leader in continuing education for retail, health-system, managed care and specialty pharmacists. PT CE is accredited by the Accreditation Council for Pharmacy Education as a provider …

Bristol-Myers

Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says - Barron’s | 9/13/2019

Bristol-Meyers Squibb Co. medication Photograph by Daniel Acker/Bloomberg Things are looking up for Bristol-Myers Squibb , according to one analyst at JPMorgan , even with the stock down 18.3% over the past 12 months. “Overall, we see far more paths to upside…than downside…for the stock from here,” wrote the bank’s Christ Schott in a note published Thursday. Scott highlighted the high price that the biotech firm Celgene …

Bristol-Myers teams with BioMotiv to build and buy biotechs | FierceBiotech | 9/4/2019

Bristol-Myers Squibb has allied with biotech accelerator BioMotiv. The deal sets Bristol-Myers up to found and fund biotechs with BioMotiv before going on to acquire them outright once a preclinical candidate is identified. BioMotiv, a biotech accelerator associated with the $380 million Harrington Project for Discovery & Development, builds companies around academic science and helps these startups get into human testing and on to deals with larger partners. In …

Bristol-Myers Squibb

Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says - Barron’s | 9/13/2019

Bristol-Meyers Squibb Co. medication Photograph by Daniel Acker/Bloomberg Things are looking up for Bristol-Myers Squibb , according to one analyst at JPMorgan , even with the stock down 18.3% over the past 12 months. “Overall, we see far more paths to upside…than downside…for the stock from here,” wrote the bank’s Christ Schott in a note published Thursday. Scott highlighted the high price that the biotech firm Celgene …

Prostate Cancer Therapeutics Market Development Plans, Size, Expected CAGR of 12.5%and Leading Industry Players: Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, etc | 9/9/2019

Bristol-Myers Squibb, Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others. Download Free Sample Copy of [email protected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-prostate-cancer-therapeutics-market utm_source=NewsSB Succinct Description of the Market: Global Prostate Cancer Therapeutics Market is expected to growing at a CAGR of 12.5% during the forecast period of 2018 to …

Gilead Sciences

4 Key Questions for Gilead Sciences’ New CEO | 9/11/2019

What’s next for Gilead? CEO Dan O’Day provided some answers this week. Keith Speights ( TMFFishBiz ) Sep 11, 2019 at 8:15AM Investors reacted positively overall to Gilead Sciences ‘ ( NASDAQ:GILD ) announcement earlier this year that Dan O’Day would be the big biotech’s next CEO. O’Day claims a solid track record at Roche , most previously serving as CEO of Roche Pharmaceuticals. After joining Gilead in March, O’Day has already begun to make …

Gilead Sciences, Inc. (GILD) CEO Daniel O’Day presents at Morgan Stanley Global Healthcare Conference (Transcript) | Seeking Alpha | 9/10/2019

Gilead Sciences, Inc. (NASDAQ: GILD ) Morgan Stanley Global Healthcare Conference Call September 10, 2019 10:00 AM ET Company Participants Daniel O’Day - Chairman and Chief Executive Officer Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison Great. So good morning, everybody. Thanks for joining us for the next session. I’m Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Just quickly, before we get started, I need to read …

Biogen

Biotech Automation and FDA Validation Expert Superior Controls to Exhibit and Recruit at the ISPE Annual Premier One-Day Biopharmaceutical Show on September 18 | PRWeb | 9/12/2019

Biotech Automation and FDA Validation Expert Superior Controls to Exhibit and Recruit at the ISPE Annual Premier One-Day Biopharmaceutical Show on September 18 Share Article Superior Controls will attend the 28th annual International Society … the company works nationally with industry leaders such as Pfizer, Biogen, GE Healthcare, Genentech, Gilead and more. Superior Controls and Banks Integration Group have four engineering offices located in Seabrook, New Hampshire, Albany, New York

RNA Expert Dr. Phillip Sharp Joins as Advisor to Skyhawk Therapeutics | PR Newswire | 9/4/2019

… those previously considered ‘undruggable.’” Phillip Sharp , Ph.D. is a world-renowned geneticist and molecular biologist who is a cofounder both Biogen and Alnylam Pharmaceuticals. He shared the 1993 Nobel Prize in Physiology or Medicine with … to his gifts as a scientist, Phil’s wide range of biotech business expertise will guide Skyhawk’s development drugs for patients with some of the most challenging conditions – from major cancers to neurological and autoimmune conditions …

GlaxoSmithKline

Avalon Ventures and COI Pharmaceuticals Announce Acquisition of Sitari Pharmaceuticals by GSK | Business Wire | 9/11/2019

SAN DIEGO- Avalon Ventures today announced that it entered into a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. Sitari has been developing a novel treatment for celiac disease and … last six years, GSK and Avalon have pioneered a unique biotech funding model designed to identify novel targets from top-tier academic labs and translate cutting-edge discoveries into promising clinical candidates,” said John Lepore

GSK buys celiac startup Sitari 6 years after founding it with Avalon | FierceBiotech | 9/11/2019

GlaxoSmithKline has struck a deal to buy Sitari Pharmaceuticals, the first company created through its collaboration with Avalon Ventures. Sitari, a preclinical-stage biotech, is developing inhibitors of the TG2 enzyme as treatments for the autoimmune digestive disorder celiac disease. GSK and Avalon came together to found Sitari in 2013. Sitari raised a $10 million series A round in the same year and then worked within Avalon’s COI Pharmaceuticals incubator …

AbbVie

Pharmacy Times Continuing Education™ to Host Directions in Oncology Pharmacy™ Conference in Chicago | Business Wire | 9/12/2019

AbbVie Company and Janssen Biotech Inc. For more information and to register for the conference, click here. About Pharmacy Times Continuing Education™ Pharmacy Times Continuing Education ™ ( PT CE) is a leader in continuing education for retail, health-system, managed care and specialty pharmacists. PT CE is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education (CPE). PT CE’s print, online and live CPE activities …

Prostate Cancer Therapeutics Market Development Plans, Size, Expected CAGR of 12.5%and Leading Industry Players: Astellas Pharma Inc, Astrazeneca Plc, Active Biotech, etc | 9/9/2019

Biotech, Abbott Laboratories, Bayer AG, Dendreon Corporation (Sanpower Group Co. Ltd.), AbbVie, Inc. among others. Download Free Sample Copy of [email protected] https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-prostate-cancer-therapeutics-market utm_source=NewsSB Succinct Description of the Market: Global Prostate Cancer Therapeutics Market is expected to growing at a CAGR of 12.5% during the forecast period of 2018 to 2025. The prostate cancer occurs in the prostate which …

Morgan Stanley

Gilead Sciences, Inc. (GILD) CEO Daniel O’Day presents at Morgan Stanley Global Healthcare Conference (Transcript) | Seeking Alpha | 9/10/2019

Gilead Sciences, Inc. (NASDAQ: GILD ) Morgan Stanley Global Healthcare Conference Call September 10, 2019 10:00 AM ET Company Participants Daniel O’Day - Chairman and Chief Executive Officer Conference Call Participants Matthew Harrison - Morgan Stanley Matthew Harrison Great. So good morning, everybody. Thanks for joining us for the next session. I’m Matthew Harrison, one of the biotech analysts here at Morgan Stanley. Just quickly, before we get started, I need to read …

iShares NASDAQ Biotechnology Index Fund (NASDAQ:IBB), SPDR S&P Biotech ETF (ETF:XBI) - The Week Ahead In Biotech: Conference Presentations, IPO News Flow Take The Spotlight | Benzinga | 9/8/2019

… 9-10, in Zurich, Switzerland H.C. Wainwright Annual Healthcare Conference 2019 – Sept. 9-10, in Lotte New York Palace Hotel, New York Morgan Stanley 17th Annual Healthcare Conference – Sept. 9-11, in Grand Hyatt, New York City, New … years with a confirmed diagnosis of peanut allergy. See Also: Biotech Stock On The Radar: Ardelyx Gears Up For FDA Decision Day Clinical Trial Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is due on Thursday to …

Goldman Sachs

ObsEva SA to Participate in Upcoming Investor Conferences | Globe Newswire | 8/30/2019

August 30, 2019 01:00 ET Source: ObsEva SA Geneva, Switzerland and Boston, MA – August 30, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating two upcoming investor conferences. The Goldman Sachs Ninth Annual Biotech Symposium taking place Friday, September …

ObsEva SA to Participate in Upcoming Investor Conferences | Markets Insider | Business Insider | 8/30/2019

Geneva, Switzerland and Boston, MA – August 30, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy, today announced that Company Management will be participating two upcoming investor conferences. The Goldman Sachs Ninth Annual Biotech Symposium taking place Friday, September 6, 2019 in London. The H.C. Wainwright 21 …

Merrill Lynch

Wall Street’s MVPs, Oracle vs. Larry Ellison, and flawed science at uBiome | Markets Insider | Business Insider | 8/25/2019

… part to play. In dealmaking, star bankers are in high demand. As Alex Morrell reported this week, Bank of America Merrill Lynch has been on an investment-banking hiring blitz , with the bank most recently … 29-year-old chief business officer of the rare-disease biotech Eidos Therapeutics , who also who worked on the listing of BridgeBio , 2019’s biggest biotech IPO. He told us the two key lessons that …

Hansa Biopharma to Participate in Three Upcoming Investor Conferences | PR Newswire | 8/21/2019

Biotech Symposium in London on Friday, September 6, 2019 . The Morgan Stanley 17th Annual Global Healthcare Conference in New York City , NY Tuesday, September 10, 2019 , with a presentation at 1:30 PM EST / 19:30 CET on the same day. The Bank of America Merrill Lynch Global Healthcare Conference 2019 in London from Thursday, September 19, 2019 to Friday, September 20, 2019 , with a presentation at 14:45 CET on Friday September …

William Blair

Krystal Biotech Inc (KRYS) Receives a Buy from William Blair | 9/4/2019

Krystal Biotech Inc (KRYS) Receives a Buy from William Blair Austin Angelo - September 4, 2019, 10:07 AM EDT SHARE ON: In a report released today, Raju Prasad from William Blair maintained a Buy rating on Krystal Biotech Inc ( KRYS ). The company’s shares closed last Monday at $42.20. According to TipRanks.com , Prasad is a 4-star analyst with an average return of 11.9% and a 49.1% success rate. Prasad covers the …

U.S. STOCKS ON THE MOVE-Bank stocks, industrials, Macy’s, Tilray - Nasdaq.com | 8/14/2019

William Blair Portola Pharma : up 1.3% Down after pricing stock offering DelMar Pharma : down 42.1% Plunges to record low on deep-discounted stock deal Adaptive Biotechnologies Corp : down 2.9% Slides after wider loss YY Inc : up 0.6% Down after Q2 profit miss Neptune Wellness : down 3.6% Not well as Q1 revenue falls Crown Crafts : up 5.3% Gains on higher Q1 profit, revenue Akari : up 30.6% Surges on FDA “fast track …

SVB Leerink

Satsuma Pharmaceuticals, a biotech targeting migraines, files for an $86 million IPO | Nasdaq | 8/17/2019

Satsuma Pharmaceuticals, a clinical-stage biotech developing a therapy for migraines, filed on Friday with the SEC to raise up to $86 million in an initial public offering. Satsuma’s lead product candidate, STS101, is a … Satsuma Pharmaceuticals filed confidentially on June 21, 2019. Credit Suisse, SVB Leerink and Evercore ISI are the joint bookrunners on the deal. No pricing terms were disclosed. The article Satsuma Pharmaceuticals, a biotech targeting migraines

Amarin Shares Show Heart as Anti-Cholesterol Drug Firm Bucks Market Rout - TheStreet | 8/14/2019

Bucking the market rout, shares of Amarin ( AMRN - Get Report ) posted a healthy increase Wednesday after a brokerage firm upgraded the heart-drug firm’s stock. Amarin rose 3.5% to $14.80 after SVB Leerink upped its rating on the biotech’s stock to outperform, saying a recent double-digit decline offers investors a buying opportunity. Amarin’s stock price plunged more than 20% on Friday after the Food and Drug Administration said it …

Third Rock Ventures

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis | Nature | 7/31/2019

Biotechnologies, AIMM Therapeutics, Allogene Therapeutics, Amgen, Merus, Neon Therapeutics, Scenic Biotech and Third Rock Ventures, reports research support from Merck, Bristol-Myers Squibb, Merck KGaA, and is stockholder in AIMM Therapeutics, Allogene Therapeutics, Merus, Neogene Therapeutics, Neon Therapeutics and Scenic Biotech, all outside the scope of this work. K.E.d.V. reports research funding from Roche and is consultant for Third Rock Ventures, outside the scope of this work. Additional information Publisher’s …

For biotech industry, a milestone: Vertex names woman as president, CEO - The Boston Globe | 7/25/2019

… Vertex Pharmaceuticals, has been chief medical officer at Vertex. (Vertex Pharmaceuticals) Score one for gender diversity in the male-dominated biotech industry. Vertex Pharmaceuticals said Thursday that its chief medical officer, Reshma Kewalramani, will take … this is entirely within reach.” Abbie Celniker, a partner at Third Rock Ventures in Boston, which invests in biotech companies, said she has seen three trends develop since the MassBio report came out in 2017 …

Silicon Valley Bank

2019 China Focus Forum @ Bio Philadelphia, Leading a New Mode of Cross-Border Healthcare Cooperation | PRWeb | 7/12/2019

Silicon Valley Bank, Cedrus Group, Rui Jian Capital, Northern Light, Share Capital and other investment institutions, as well as PricewaterhouseCoopers, Frost&Sullivan and other well-known consulting firm. The whole China Focus Forum was divided into four parts, composed of the main forum on “Cross-border Collaboration in Biotech and Pharma” and “AI and Digital Health”, Pitch and Match, MyBioGate Global Healthcare Innovation Competition, and the exhibition. During the forum …

2019 China Focus Forum @ Bio Philadelphia, Leading a New Mode of Cross-Border Healthcare Cooperation - Yahoo Finance | Yahoo News | 7/12/2019

… opportunities and challenges with cross-border investment and partnership, impact of AI on pharmaceutical industry, as well as emerging Chinese biotech & pharma industry. /b “ data-reactid=”11” The Forum organized by MyBioGate focused on the … Johnson, Novartis, GlaxoSmithKline, Janssen, numerous Chinese and foreign drug companies, Silicon Valley Bank, Cedrus Group, Rui Jian Capital, Northern Light, Share Capital and other investment institutions, as well as PricewaterhouseCoopers, Frost&Sullivan and other well …

Versant Ventures

Versant Ventures Enables Launch of Vensana Capital to Focus on Medtech Sector | Business & Finance | heraldchronicle.com | Business Wire | 9/4/2019

Versant Ventures Enables Launch of Vensana Capital to Focus on Medtech Sector Sep 4, 2019 Save SAN FRANCISCO & NEW YORK & VANCOUVER, British Columbia & BASEL, Switzerland–(BUSINESS WIRE)–Sep 4, 2019– Since it was conceived, Versant … to collaborate on any new opportunities that cross over the biotechnology and medtech sectors. Furthermore, the Versant finance organization is providing back office support for the new medtech fund. About Versant Ventures Versant Ventures is

Therapeutics startup raises $65M in latest round to fight kidney disease | The Business Journals | 8/24/2019

… in the U.S. have been diagnosed with the disease. The recent funding, which was announced Thursday, comes from founding investors Versant Ventures and Apple Tree Partners. Samsara BioCapital also invested. The money will go toward … the role at Chinook, Dobmeier was CEO of another Seattle biotech company, Silverback Therapeutics. After that company hit a preclinical setback, Dobmeier moved on to Chinook, he said. – Staff Writer, Puget Sound Business Journal Aug …

ARCH Venture Partners

HiberCell Strengthens Leadership Team with Appointment of Colin Goddard to Board of Directors | PR Newswire | 8/6/2019

NEW YORK HiberCell , a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, today announced the appointment of Colin Goddard to the company’s Board of Directors. The company also announced that Steven Gillis … in Birmingham, United Kingdom . Gillis is a managing director of ARCH Venture Partners, where he focuses on the evaluation of new life science technologies and the development of ARCH’s biotechnology portfolio companies. He is a

ImmusanT cans phase 2 celiac trial after interim efficacy review | FierceBiotech | 6/26/2019

ImmusanT has stopped a phase 2 trial of its lead candidate in celiac disease after an interim analysis. The analysis found Nexvax2 was no better than placebo at protecting patients from gluten exposure, prompting the Arch Venture Partners-backed biotech to stop the study. Massachusetts-based ImmusanT tapped Arch and Vatera Healthcare Partners for $40 million in 2017 and embarked on a phase 2 trial designed to demonstrate the potential …

RBC Capital Markets

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/8/2019

… and Chief Medical Officer Conference Call Participants Alethia Young - Cantor Fitzgerald Tazeen Ahmad - Bank of America Merrill Lynch Brian Abrahams - RBC Capital Markets Christopher Marai - Nomura Vincent Chen - Bernstein Brian Skorney - Robert W. Baird Danielle … of sufficient and rapid development and approval pathways in our biotech. Showing the consistency and precision of our RNA platform, we announced positive results for casimersen in the first quarter and we intend to submit …

PTC Therapeutics, Inc. (PTCT) CEO Stuart Peltz on Q2 2019 Results - Earnings Call Transcript | Seeking Alpha | 8/7/2019

… June 30, 2019, compared to approximately $227 million at December 31, 2018. We are proud to have built a global biotech company that is in a financial position to continue to execute on our long … Thank you. Our next question comes from Brian Abrahams of RBC Capital Markets. Your line is open. Unidentified Analyst Hi. This is Bert on for Brian. Thank you guys for taking our question. I had …

HCA

Private equity companies acquire virtual research firm Thread | MedCity News | 8/27/2019

… of the deal were not disclosed. However, Thread said it would use the investment - from JLL Partners and Water Street Healthcare Partners - to accelerate the expansion of its service offering globally. Post a comment / at … June, one participant in a panel of experts at the Biotechnology Innovation Organization about diversity in clinical trials noted that a tank of gas to drive to a trial site and parking that costs $40 …

Telehealth Has An Awareness Problem | Forbes | 8/27/2019

Two-thirds of adults are willing to consult with a doctor via video, but only 8% have tried it, according to a new consumer survey by American Well, a major provider of telehealth services. The poll closely tracks other studies that show consumers have been slow to adopt telehealth (also known as telemedicine), despite the fact that more health plans and self-insured employers are offering it as a benefit …

MD Anderson Cancer Center

Biotech execs criticize government crackdown on Chinese scientists | MedCity News | 8/22/2019

More than 150 people - including biotechnology and investment executives and academics - have signed a letter warning that actions dismissals of Chinese scientists create a hostile climate that threatens U.S. leadership in biomedical science. Post a … at institutions like the NIH and The University of Texas MD Anderson Cancer Center. In a June article , the South China Morning Post Magazine reported that “ways of working that have long been encouraged” by

Biotech leaders speak out against dismissals of Chinese scientists - FierceBiotech (1 visits) | 8/22/2019

… a climate of fear and uncertainty in our biomedical communities,” wrote Jeremy Levin, Ovid Therapeutic CEO and Chairman of the Biotechnology Innovation Organization, along with Alnylam CEO John Maraganore, Decibel CEO Steven Holtzman, and Acorda … well-publicized dismissal of five scientists—all Asian-American—from MD Anderson Cancer Center and Emory University . Other universities have fired researchers quietly, in cases that have stayed confidential, Michael Lauer, head of NIH’s extramural …

Memorial Sloan Kettering

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

… bln August 8, 2019 Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research. PRESS RELEASE Versant Ventures Announces Acquisition of Cell Therapy … Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New York, key management talent, intellectual property, as well as manufacturing expertise from partners. In December 2016, BlueRock came out of …

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics | Business Wire | 8/8/2019

… technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New York, key management talent, intellectual property, as well as manufacturing … precision medicine, gene editing and gene therapy. “Constructing early stage biotech portfolios from promising yet unproven areas of scientific innovation has taught us to be flexible about how we form, finance and exit companies,” said …

Harvard Medical School

Alpha Tau Medical Appoints Jefferson University Radiation Oncologist Robert Den as Chief Medical Officer | PR Newswire | 9/4/2019

… helping clinicians around the world unleash its full potential.” Dr. Den attended Yale University , and received his medical degree from Harvard Medical School in 2006. He performed his internship at Massachusetts General Hospital and residency … Founded in 2016, Alpha Tau Medical Ltd. is an Israeli biotech company that focuses on R&D and commercialization of the first alpha-radiation based cancer treatment for solid tumors, Alpha DaRT . For more information …

Atlas Biotechnologies Announces European Expansion | Globe Newswire | 9/3/2019

September 03, 2019 05:00 ET Source: Atlas Biotechnologies Inc. EDMONTON, Alberta, Sept. 03, 2019 (GLOBE NEWSWIRE) – Atlas Biotechnologies Inc. (“Atlas” or the “Company”) is pleased to announce Atlas Growers Denmark A/S, a major European … some of the world’s most prestigious post-secondary institutions including Harvard Medical School. Atlas continues towards its’ vision of improving lives by creating The World’s Most Trusted Cannabis Products™. Forward-Looking Information This news release

Memorial Sloan Kettering Cancer Center

Health Care Sector Update for 07/22/2019: KZIA,DVA,FGEN,DVA,NTEC - Nasdaq.com | 7/22/2019

Biotechnology index was climbing almost 0.4%. Among health care stocks moving on news: (+) Kazia Therapeutics Ltd ( KZIA ) rose more than 13% after the Australian company said the Memorial Sloan Kettering Cancer Center in New York will investigate the potential use of a combination of radiotherapy and the company’s GDC-0084 drug candidate during a phase I clinical trial in patients whose cancer has spread to their brains. The first part …

White House Yanks Drug ‘Rebate’ Plan to Lower Costs for Some | U.S. News & World Report | 7/11/2019

… This is a big setback,” said Peter Bach, director of the Center for Health Policy and Outcomes at New York’s Memorial Sloan Kettering Cancer Center. The rebate rule “was not good policy (since) it would … for the medicines they need,” Jim Greenwood, head of the Biotechnology Innovation Organization, said in a statement. Shares of pharmaceutical companies dropped Thursday but drug store chains and insurers gained. Drugmaker Merck & Co. dropped 4.5 …

Mayo Clinic

Biotech Brief: Latest Electrophysiology Devices Vastly Improving Diagnosis and Treatment of Cardiovascular Diseases Nasdaq:BSGM | Globe Newswire | 9/12/2019

… address an unmet technology need for the electrophysiology (EP) marketplace, today announced that it signed a new licensing agreement with Mayo Clinic. The new agreement aims to develop a new product pipeline to support some … icosapent ethyl). Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological and neuropsychiatric diseases, recently announced completion of enrollment in its Phase 2/3, double-blind, randomized, placebo …

Mayo Clinic Cancer Center Renews NCI Research Funding | 9/12/2019

Mayo Clinic Cancer Center Renews NCI Research Funding Biotech Mag Top Mayo Clinic Cancer Center has successfully renewed funding for its Cancer Center Support Grant from the National Cancer Institute. The NCI grant award provides approximately …

Massachusetts General Hospital

Alpha Tau Medical Appoints Jefferson University Radiation Oncologist Robert Den as Chief Medical Officer | PR Newswire | 9/4/2019

… Den attended Yale University , and received his medical degree from Harvard Medical School in 2006. He performed his internship at Massachusetts General Hospital and residency at Thomas Jefferson University. Today, he treats a wide array … Founded in 2016, Alpha Tau Medical Ltd. is an Israeli biotech company that focuses on R&D and commercialization of the first alpha-radiation based cancer treatment for solid tumors, Alpha DaRT . For more information …

CURE Pharmaceutical Expands Board with Two Women Directors | Globe Newswire | 8/7/2019

… Chung was a recognized research scientist conducting cutting-edge research in the field of Alzheimer’s disease and Angelman Syndrome at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital, respectively. Dr. Chung has published … array of products in innovative delivery platforms and partners with biotech and pharmaceutical companies. CURE has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, and …

University of Texas MD Anderson Cancer Center

Biotech execs criticize government crackdown on Chinese scientists | MedCity News | 8/22/2019

More than 150 people - including biotechnology and investment executives and academics - have signed a letter warning that actions dismissals of Chinese scientists create a hostile climate that threatens U.S. leadership in biomedical science. Post a … in biomedical research at institutions like the NIH and The University of Texas MD Anderson Cancer Center. In a June article , the South China Morning Post Magazine reported that “ways of working that have long

Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019 | PR Newswire | 8/17/2019

HOUSTON , Aug. 16, Moleculin Biotech, Inc., (NASDAQ: MBRX ) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the … was the announcement that our ongoing sponsored research at The University of Texas MD Anderson Cancer Center resulted in the discovery that Annamycin, our lead drug candidate for the treatment of acute myeloid leukemia, has

The University of Texas MD Anderson Cancer Center

Biotech execs criticize government crackdown on Chinese scientists | MedCity News | 8/22/2019

More than 150 people - including biotechnology and investment executives and academics - have signed a letter warning that actions dismissals of Chinese scientists create a hostile climate that threatens U.S. leadership in biomedical science. Post a … involved in biomedical research at institutions like the NIH and The University of Texas MD Anderson Cancer Center. In a June article , the South China Morning Post Magazine reported that “ways of working that have

Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019 | PR Newswire | 8/17/2019

HOUSTON , Aug. 16, Moleculin Biotech, Inc., (NASDAQ: MBRX ) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the … quarter was the announcement that our ongoing sponsored research at The University of Texas MD Anderson Cancer Center resulted in the discovery that Annamycin, our lead drug candidate for the treatment of acute myeloid leukemia

Tenet Healthcare

Tenet Healthcare (THC) Q2 Earnings: What’s in the Cards? - August 2, 2019 - Zacks.com | 8/2/2019

Tenet Healthcare Corporation ( THC - Free Report ) will report second-quarter 2019 results on Aug 5, after market close. In the last reported quarter, it delivered adjusted net earnings of 54 cents per share, outperforming the … complete list of today’s Zacks 1 Rank stocks here . Adverum Biotechnologies, Inc. ( ADVM - Free Report ) has an Earnings ESP of +14.75%. This 3 Ranked company is set to report second-quarter financial numbers on Aug

Aetna

3 Embarrassingly Cheap Dividend Stocks - Nasdaq.com | 8/11/2019

… earnings. There are a couple of reasons behind CVS Health’s low valuation. Many were skeptical about the company’s acquisition of Aetna last year. With several presidential candidates advocating changes that would negatively impact the health … Gilead Sciences Gilead Sciences is something of a rarity: a biotech that pays a dividend. The company’s dividend yields 3.85%. Its stock is also attractively valued, with shares trading at eight times expected earnings. The …

Cigna

Here’s Why Cigna (CI) is an Attractive Investment Option Now - August 29, 2019 - Zacks.com | 8/29/2019

The stock of Cigna Corp. ( CI - Free Report ) witnessed the Zacks Consensus Estimate for current-year earnings being revised 1.4% upward over the last 30 days. This shows analyst’s optimism over the company’s favorable performance, driven by the recently closed acquisition of Express Scripts. The addition of Express Scripts has provided diversification to Cigna’s existing businesses – administrative services, international operations, and disability and life insurance, which are already performing well …

Health Net

Bayer AG buys BlueRock Therapeutics for $1 bln | PE Hub | 8/8/2019

… bln August 8, 2019 Bayer AG has acquired BlueRock Therapeutics from Versant Ventures for up to $1 billion. BlueRock, a biotech, focuses on stem cell research. PRESS RELEASE Versant Ventures Announces Acquisition of Cell Therapy … technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New York, key management talent, intellectual property, as well as manufacturing …

Versant Ventures Announces Acquisition of Cell Therapy Company BlueRock Therapeutics | Business Wire | 8/8/2019

… over 12 months allowing the necessary time to secure foundational technology from the McEwen Stem Cell Institute at the University Health Network in Toronto and the Stem Cell Center at Memorial Sloan Kettering in New … precision medicine, gene editing and gene therapy. “Constructing early stage biotech portfolios from promising yet unproven areas of scientific innovation has taught us to be flexible about how we form, finance and exit companies,” said …

Clover Health

Top CEOs at Goldman Sachs, Salesforce, Novartis talk strategy - Business Insider | 7/19/2019

Biotechnologies , a $5.6 billion biotech that just had the year’s best post-IPO pop. He talked to us about how it’s partnering with Microsoft to build an enormous map of the human immune system . We talked to Vivek Garipalli , the CEO and founder of health insurer Clover Health , which set out to upend healthcare for aging Americans. He explained why, five years and $925 million in funding later, it’s proving …

WHAT YOUR BOSS IS THINKING: We talk to the top CEOs in the world about their strategy | Markets Insider | Business Insider | 7/19/2019

Biotechnologies , a $5.6 billion biotech that just had the year’s best post-IPO pop. He talked to us about how it’s partnering with Microsoft to build an enormous map of the human immune system . We talked to Vivek Garipalli , the CEO and founder of health insurer Clover Health , which set out to upend healthcare for aging Americans. He explained why, five years and $925 million in funding later, it’s proving …

Anthem

Healthcare And Biotechnology Dashboard - Update - iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) | Seeking Alpha | 6/18/2019

… in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks significantly underpriced relative to its historical averages in all the valuation metrics reported … among S&P 500 healthcare stocks in this period are Anthem Inc. ( ANTM ), Cooper Cos. Inc. ( COO ), Illumina Inc. ( ILMN ), Medtronic PLC ( MDT ), and Mettler-Toledo International Inc. ( MTD ). Some cheap stocks in their industries …

U.S. STOCKS ON THE MOVE-Qualcomm, BNY Mellon, Domino’s, PepsiCo, Sprint - Nasdaq.com | 4/17/2019

… up 5.9 pct The top three S&P 500 percentage losers: Bank of New York Mellon Corp down 8 pct Anthem Inc down 4.5 pct Pentair Plc down 4.4 pct The top NYSE percentage gainers … Chipotle Mexican Grill: Morgan Stanley downgrades to ‘equal-weight’ Moleculin Biotech Inc : up 11.0 pct Jumps on new data from cancer drug testing DPW Holdings Inc : up 19.8 pct Soars on bright outlook Bank of …

UnitedHealthcare

Another hit for Roche: UnitedHealthcare backs Amgen biosims over blockbuster oncology meds | FiercePharma | 8/16/2019

… preferred status over biosimilar competitors from Celltrion and Pfizer, Samsung Bioepis, and Merck, among others. The only other biosim that UnitedHealthcare flagged as preferred was a Neupogen copy from Novartis’ Sandoz unit, which now is … this year. A Rituxan copy from Fosun Pharma’s Shanghai Henlius Biotech was the first-ever biosim approved in China, foreshadowing the legacy megablockbuster’s continued decline overseas. In Europe, where Rituxan biosims have already dropped, sales …

Molina Healthcare

Validea’s Top Five Healthcare Stocks Based On Joel Greenblatt - 5/19/2019 - Nasdaq.com | 5/19/2019

… companies with high return on capital and earnings yields. AMERISOURCEBERGEN CORP. ( ABC ) is a large-cap growth stock in the Biotechnology & Drugs industry. The rating according to our strategy based on Joel Greenblatt is 100 … full detailed analysis using NASDAQ’s Guru Analysis tool, click here MOLINA HEALTHCARE, INC. ( MOH ) is a mid-cap value stock in the Healthcare Facilities industry. The rating according to our strategy based on Joel Greenblatt …

Donald Trump

This index is making a hidden bet on biotechs - MarketWatch | 8/27/2019

… indexes. The Russell 2000 RUT, -1.37% , the closely followed small-cap index, is in effect making a similar bet on biotech, according to analysis from strategists Tavis McCourt and Leslie Vandegrift at Raymond James in … 269-point burst for the Dow industrials, triggered by President Donald Trump’s claim of calls from China to restart trade talks. The yield on the 2-year Treasury TMUBMUSD02Y, -1.36% was once again higher than …

Trump Optimism May Lead To Rebound On Wall Street | Markets Insider | Business Insider | 8/26/2019

… likely to regain ground following the sell-off seen last Friday. The markets may benefit from bargain hunting as President Donald Trump has continued to express optimism about a potential U.S.-China trade deal despite … is moving notably higher in pre-market trading after the biotech company agreed to sell the global rights to its psoriasis drug Otezla to Amgen (AMGN) for $13.4 billion in cash in connection with its …

Conor Hale

FDA clears GE spinout’s less-painful blood draw device for testing A1c | FierceBiotech | 8/23/2019

by Conor Hale Aug 23, 2019 11:09am After the push-button device is placed on the skin, the sample is collected without any sight of blood or needles, using tiny lancets and light suction. (Pixabay … clinical laboratory. FREE DAILY NEWSLETTER Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for

Miracor secures FDA breakthrough status for its heart attack device - FierceBiotech | 8/22/2019

by Conor Hale Aug 22, 2019 12:25pm The device’s balloon intermittently blocks blood from flowing out through the coronary sinus veins, redirecting and pushing circulation to the oxygen-deprived areas of the heart muscle. (Wikimedia … the company. FREE DAILY NEWSLETTER Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for

Daniel O’Day

EuroBiotech Report—R&D execs leave Adaptimmune and Zealand, Wellington fund, Gilead and Woodford | FierceBiotech | 8/1/2019

Aug 1, 2019 9:40am (Pixabay) Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with news of departures from two biotechs. The week began with Zealand Pharma revealing Andrew Parker … 4. Gilead looks to Galapagos deal to double research capacity Daniel O’Day has framed Gilead Sciences’ $5.1 billion (€4.6 billion) megadeal with Galapagos as a way to double its research capacity. The Gilead CEO told

Nick Taylor

EuroBiotech Report—Merck-Themis, Juvenescence financing, GSK filing and NuCana fail | FierceBiotech | 8/22/2019

Welcome to the latest edition of our weekly EuroBiotech Report. We start this week with Themis, which unveiled a vaccine R&D pact with Merck, its first such deal with an industry player. Merck is … of its pancreatic cancer candidate early for futility. And more. — Nick Taylor 1. Merck teams up with Themis to develop vaccines Merck has struck a deal to work with Themis Bioscience on vaccine R&D

Walter Klemp

Moleculin Announces CTRC Approval of WP1066 Pediatric Brain Tumor Trial | PR Newswire | 8/20/2019

HOUSTON , Aug. 20, 2019 /PRNewswire/ – Moleculin Biotech, Inc., (Nasdaq: MBRX ) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced approval by the … trial with investigators from Emory University School of Medicine ,” commented Walter Klemp , Moleculin’s Chairman and CEO. “With CTRC approval, the investigators can now submit a request for IND from the FDA for this indication referencing

Cancer Drugs Projected to Generate the Most in Pharma Revenues | PR Newswire | 8/20/2019

… Treatment market alone is expected to grow at a CAGR of approximately 10.1% during the forecast period, 2017–2023. Active biotech and pharma companies in the markets this week include Moleculin Biotech, Inc. (NASDAQ: MBRX … trial with investigators from Emory University School of Medicine ,” commented Walter Klemp , Moleculin’s Chairman and CEO. “With CTRC approval, the investigators can now submit a request for IND from the FDA for this indication referencing …

Jim Greenwood

Prescription drug import plan offered by Trump administration | Modern Healthcare | 7/31/2019

Jim Greenwood, CEO of the Biotechnology Innovation Organization, said there is “no way to adopt an importation scheme that doesn’t jeopardize the health and well-being of America’s patients.” “This is a misguided attempt to keep an ill-informed campaign promise,” Greenwood continued. “The burden is on the leadership of the Department of Health and Human Services to ensure this actually leads to lower costs for consumers — not just for …

BIO Asia-Taiwan 2019 Showcased Biotech as the Region’s Next Growth Engine | Business Wire | 7/29/2019

TAIPEI, Taiwan–(BUSINESS WIRE)–Jul 29, 2019– One of the largest events on this year’s Asian biotechnology calendar brought together more than 1,500 people from 25 countries to meet and explore business opportunities in Taiwan’s … hub for biomedical research and development in the Asia-Pacific. Jim Greenwood, President and CEO of BIO, delivered Opening Ceremony remarks, where he expressed optimism for continued industry growth, both in Taiwan and globally. “I

Chad Robins

Adaptive Biotechnologies Executes Lease for New 100,000 Square Foot Corporate Headquarters, Tripling its Footprint in Seattle’s Growing Biotech Hub | Globe Newswire | 8/7/2019

… by Alexandria Real Estate Equities, Inc. is underway with occupancy expected in 2021 August 07, 2019 08:30 ET Source: Adaptive Biotechnologies SEATTLE, Aug. 07, 2019 (GLOBE NEWSWIRE) – Adaptive Biotechnologies Corporation (Nasdaq: ADPT ), a commercial-stage … we believe will transform medicine and improve patients’ lives,” said Chad Robins, chief executive officer and co-founder of Adaptive. “This space will support Adaptive’s strategic growth trajectory, provide our current and future employees with …

Alexandria Real Estate Equities, Inc. Enhances and Extends Long-Term Strategic Relationship With Adaptive Biotechnologies Corporation With the Signing of a 12-Year, Full-Building HQ Lease at 1165 Eastlake, a 100,000 RSF Development in the Heart of Its Lake Union Life Science Cluster in Seattle | PR Newswire | 8/7/2019

… developer uniquely focused on collaborative life science, technology and agtech campuses in AAA innovation cluster locations, today announced that Adaptive Biotechnologies Corporation has signed a 12-year, full-building lease at 1165 Eastlake Avenue East … our presence in our new headquarters on Lake Union,” said Chad Robins , chief executive officer and co-founder of Adaptive. “This expansion will provide us with improved space and amenities that will enable us to …

Bernie Sanders

Friday, August 23, 2019 | Kaiser Health News | 8/23/2019

… putting political calculation before true conviction. Joe Biden’s campaign dismisses it as a “have-it-every-which-way” plan while Bernie Sanders’ camp ripped it as “cobbled together to address various poll numbers.” (Cadelago and … 24. (Burton, 8/22) Bloomberg: The FDA Is Flexing Its Muscles Biotechnology companies often have both devoted fans and detractors. But there’s one constituency they’d be wise not to anger: U.S. regulators. In the past few …

First Edition: August 22, 2019 | Kaiser Health News | 8/22/2019

… of Education said would mean loans are forgiven unless veterans opt out. (Behrmann and Kenning, 8/21) The Washington Post: Sen. Bernie Sanders Changes How Medicare-For-All Plan Treats Union Contracts In Face Of Opposition … classify because they straddle the line between AI and traditional biotech — but its rapid growth is a clear sign of an industry on the rise. (Robbins, 8/22) The New York Times: Their Mothers Chose Donor …

Fred Hutchinson

CRISPR slows the growth of triple-negative breast cancer in mice | FierceBiotech | 8/26/2019

… the results in the journal Proceedings of the National Academy of Sciences. FREE DAILY NEWSLETTER Like this story? Subscribe to FierceBiotech! Biopharma is a fast-growing world where big ideas come along every day. Our … gene-editing research. Earlier this year, a team at the Fred Hutchinson Cancer Research Center said it developed gold nanoparticles that can deliver CRISPR with no toxic side effects. GenEdit , a spinoff from the University …

Fortress Biotech Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights | Globe Newswire | 8/9/2019

August 09, 2019 16:05 ET Source: Fortress Biotech, Inc. NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) – Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on identifying, in-licensing and developing high-potential … its full potential, including Alexion Pharmaceuticals, Inc., City of Hope, Fred Hutchinson Cancer Research Center, InvaGen Pharmaceuticals, Inc. (a subsidiary of Cipla Limited) and St. Jude Children’s Research Hospital. For more information, visit www.fortressbiotech.com . Forward

Shai Yarkoni

Cellect Biotechnology Reports Second Quarter 2019 Financial and Operating Results | PR Newswire | 8/13/2019

TEL AVIV, Israel , Aug. 13, Cellect Biotechnology Ltd. (NASDAQ: APOP ), a developer of innovative technology which enables the functional selection of stem cells, today reported financial and operating results for the second quarter ended June 30, 2019 and provided a corporate update. “We are making solid clinical progress in Israel and we are optimistic as we move closer to commencing our first clinical trial in the U.S.,” commented Dr. Shai …

Cellect Biotechnology Announces Positive Outcome From Safety Review Committee; Successfully Transplants 9th Clinical Trial Patient | PR Newswire | 8/12/2019

… month data of the 9 th patient, the Data and Safety Monitoring Board (DSMB) reviewed the safety data from Cellect Biotechnology Ltd.’s (Nasdaq: APOP ) ongoing Phase 1/2 clinical study of ApoGraft™, and announced that … are increasingly pleased with our global clinical progress,” commented Dr. Shai Yarkoni , Chief Executive Officer. “In Israel, the DSMB’s recommendation to proceed to the final cohort of our ApoGraft study without modification furthers us towards …